Related references
Note: Only part of the references are listed.Antifungal Lock Therapy
Carla J. Walraven et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Inhibitors of V-ATPase Proton Transport Reveal Uncoupling Functions of Tether Linking Cytosolic and Membrane Domains of V0 Subunit a (Vph1p)
Chun-Yuan Chan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target
Anjan Debnath et al.
NATURE MEDICINE (2012)
Role of Fks1p and Matrix Glucan in Candida albicans Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene
Jeniel E. Nett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
FDA Regulations for Drug Development
Rachel E. Behrman et al.
SCIENCE (2010)
Our Current Understanding of Fungal Biofilms
Gordon Ramage et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2009)
Amphotericin B and Its New Derivatives - Mode of Action
M. Baginski et al.
CURRENT DRUG METABOLISM (2009)
Outcome of Antimicrobial Therapy in Documented Biofilm-Associated Infections A Review of the Available Clinical Evidence
Matthew E. Falagas et al.
DRUGS (2009)
Effect of tunicamycin on Candida albicans biofilm formation and maintenance
Christopher G. Pierce et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Amphotericin B: side effects and toxicity
Rafael Laniado-Laborin et al.
REVISTA IBEROAMERICANA DE MICOLOGIA (2009)
Alexidine and chlorhexidine bind to lipopolysaccharide and lipoteichoic acid and prevent cell activation by antibiotics
Mateja Zorko et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing
Christopher G. Pierce et al.
NATURE PROTOCOLS (2008)
A review of thimerosal (merthiolate) and its ethylmercury breakdown product: Specific historical considerations regarding safety and effectiveness
David A. Geier et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS (2007)
Candida biofilms on implanted biomaterials:: a clinically significant problem
Gordon Ramage et al.
FEMS YEAST RESEARCH (2006)
Candida infections of medical devices
EM Kojic et al.
CLINICAL MICROBIOLOGY REVIEWS (2004)
Candida biofilm resistance
PK Mukherjee et al.
DRUG RESISTANCE UPDATES (2004)
Prediction of mechanisms of action of antibacterial compounds by gene expression profiling
B Hutter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H- pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation
H Esumi et al.
CANCER SCIENCE (2004)
Quantitative binding models for CYP2C9 based on benzbromarone analogues
CW Locuson et al.
BIOCHEMISTRY (2004)
Antifungal agents: mechanisms of action
FC Odds et al.
TRENDS IN MICROBIOLOGY (2003)
Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit
KI Jeon et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2003)
Attributable mortality of nosocomial candidemia, revisited
O Gudlaugsson et al.
CLINICAL INFECTIOUS DISEASES (2003)
Candida biofilms and their role in infection
LJ Douglas
TRENDS IN MICROBIOLOGY (2003)
In vitro activity of caspofungin against Candida albicans biofilms
SP Bachmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Antifungal susceptibility of Candida biofilms:: Unique efficacy of amphotericin B lipid formulations and echinocandins
DM Kuhn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Chemotherapeutic approaches to trematodes (except schistosomes) and cestodes: current level of knowledge and outlook
A Harder
PARASITOLOGY RESEARCH (2002)
Biofilms: Survival mechanisms of clinically relevant microorganisms
RM Donlan et al.
CLINICAL MICROBIOLOGY REVIEWS (2002)
Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms
G Ramage et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
